Connor, Clark & Lunn Investment Management (CC&L)’s Alexion Pharmaceuticals ALXN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,842	Closed	-$1.81M	–	1277
2021 Q2	$1.81M	Sell	9,842 -2,708	-22%	-$465K	0.01%	562
2021 Q1	$1.92M	Buy	12,550 +596	+5%	+$92.2K	0.01%	568
2020 Q4	$1.87M	Buy	+11,954	New	+$1.54M	0.01%	523
2020 Q3	–	Sell	-8,742	Closed	-$981K	–	1187
2020 Q2	$981K	Sell	8,742 -116,568	-93%	-$12.4M	0.01%	618
2020 Q1	$11.3M	Sell	125,310 -113,405	-48%	-$11.1M	0.1%	142
2019 Q4	$25.8M	Buy	238,715 +133,475	+127%	+$14.3M	0.18%	101
2019 Q3	$10.3M	Buy	105,240 +77,175	+275%	+$8.7M	0.07%	172
2019 Q2	$3.68M	Buy	28,065 +23,850	+566%	+$3.07M	0.02%	336
2019 Q1	$570K	Buy	4,215 +575	+16%	+$71.5K	﹤0.01%	644
2018 Q4	$354K	Sell	3,640 -36,768	-91%	-$4.35M	﹤0.01%	770
2018 Q3	$5.62M	Sell	40,408 -69,475	-63%	-$8.72M	0.03%	299
2018 Q2	$13.6M	Sell	109,883 -105,475	-49%	-$12.3M	0.08%	182
2018 Q1	$24M	Buy	215,358 +21,858	+11%	+$2.61M	0.15%	120
2017 Q4	$23.1M	Buy	193,500 +87,550	+83%	+$10.7M	0.14%	130
2017 Q3	$14.9M	Buy	105,950 +62,275	+143%	+$8.46M	0.09%	155
2017 Q2	$5.31M	Buy	43,675 +40,975	+1,518%	+$4.77M	0.03%	263
2017 Q1	$327K	Sell	2,700 -3,500	-56%	-$451K	﹤0.01%	713
2016 Q4	$759K	Buy	6,200 +2,100	+51%	+$257K	0.01%	534
2016 Q3	$502K	Sell	4,100 -3,600	-47%	-$463K	﹤0.01%	580
2016 Q2	$899K	Sell	7,700 -7,600	-50%	-$1.08M	0.01%	486
2016 Q1	$2.13M	Sell	15,300 -18,575	-55%	-$2.73M	0.02%	325
2015 Q4	$6.46M	Sell	33,875 -21,725	-39%	-$3.79M	0.05%	185
2015 Q3	$8.7M	Buy	+55,600	New	+$10.1M	0.07%	139
2014 Q2	–	Sell	-2,053	Closed	-$345K	–	664
2014 Q1	$345K	Sell	2,053 -5,000	-71%	-$795K	﹤0.01%	545
2013 Q4	$996K	Buy	+7,053	New	+$846K	0.01%	369

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ALXN Position: Q3 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 9,842 shares — an estimated $1.81M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ALXN in Q4 2013 and held it in 25 quarters. The position peaked at $25.8M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 9,842 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.81M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 25 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Alexion Pharmaceuticals position peaked at $25.8M in Q4 2019.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2021, filed 12 Nov 2021.